- Details
- Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic castrati...
|
- Details
- Karim Fizazi joins Alicia Morgans in discussing the 2021 European Society for Medical Oncology (ESMO) presentation of the results from the ODENZA trial comparing darolutamide and enzalutamide, with a focus on cognitive assessment. ODENZA is a French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomat...
|
- Details
- Alicia Morgans is joined by Richard Cathomas to highlight his oral presentation at the European Society of Medical Oncology (ESMO) 2021 annual meeting on SAKK 08/16, a phase 2 international multicenter study placebo-controlled, double-blind study of using maintenance darolutamide in patients with metastatic castration-resistant prostate cancer previously treated with novel hormonal agents and non-...
|
- Details
- Alicia Morgans and Cora Sternberg discuss the ESMO 2021 presentation on the impact of circulating tumor cell (CTC) morphologic sub-types in blood samples prior to treatment in the CARD trial. The objective of this pre-planned CARD Trial, EPIC biomarker study was to analyze the morphology of CTC subtypes in a liquid biopsy looking at chromosomal instability. Dr. Sternberg highlights the findings fr...
|
- Details
- Ravi Madan joins Alicia Morgans to discuss his presentation during the European Society for Medical Oncology (ESMO) Annual Congress assessing enzalutamide with or without vaccine therapy for advanced prostate cancer. This was a semi-automated method of assessing Sodium Fluoride (NaF) PET using a novel technology in a randomized phase II trial combining vaccine therapy with PROSTVAC and enzalutamid...
|
- Details
- Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...
|
- Details
- In a discussion hosted by Alicia Morgans, Neeraj Agarwal delves into the promising results of the COSMIC-021 study. The study focuses on the combination of cabozantinib and atezolizumab for treating patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in...
|
- Details
- Rahul Aggarwal joins Alicia Morgans describing this first-in-human study of the safety and preliminary efficacy of FOR46 in metastatic castration-resistant disease (mCRPC) patients. FOR46 is a vc-MMAE antibody-drug conjugate that recognizes a tumor-selective epitope of Cluster of differentiation 46 (CD46). FOR46 binds to CD46 with high affinity and demonstrates anti-tumor activity in prostate canc...
|
- Details
- Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...
|
- Details
- Giuseppe Procopio joins Alicia Morgans in a discussion on the BONSAI trial focused on new treatments for patients with metastatic collecting duct renal cell carcinoma. BONSAI is a phase 2 prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma. Metastatic collecting duct carcinoma is a rare and aggressive disease, characterized by a poor prognosis. The BONSA...
|
